Skip to content
Screener

Regeneron Pharmaceuticals REGN Q2 2026 earnings

Reported July 30, 2026 · Before market open

Revenue$4.3BBeat by $473.4M
Adjusted EPS$14.29Beat by $4.13
Revenue estimate$3.8B
EPS estimate$10.16
“Of note, global Dupixent, global Libtayo, and U.S. EYLEA HD net product sales increased by 38%, 30%, and 52%, respectively, compared to the second quarter of 2025. With approximately 50 clinical assets, we remain focused on translating our science into even more successful new medicines across a broad array of diseases.”
Leonard S. Schleifer

Next report

Oct 30, 2026 (In 3 weeks)
Revenue estimate$4.5B
EPS estimate$15.99

Financials

Q2 2026

Income statement

See full
Revenue$4.3B+16.7%
Operating income$1.3B+19.8%
Net income$1.3B-6.8%
EPS (diluted)$12.23-4.5%

Balance sheet

See full
Cash & equivalents$2.5B+22.3%
Total debt$2.7B+0.1%
Total equity$31.7B+5.9%
Total assets$41.7B+9.2%

Cash flow

See full
Operating cash flow$813.0M-29.0%
CapEx$240.2M+9.7%
Free cash flow$572.8M-38.1%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$75.65B+19.0%
Enterprise value$75.89B+19.0%
P/E17.5×+3.6×
P/S4.9×+0.4×

Profitability

See full
Operating margin24.7%-2.3pp
Net margin27.9%-3.5pp
FCF margin24.2%-2.9pp

Returns & leverage

See full
Return on equity14%-1.3pp
Debt / equity0.1×0.0×
Current ratio3.3×-1.3×

Segments

By product

See full
Reimbursement Of Commercialization Related Expenses$188.8M—
Reimbursement For Manufacturing Of Commercial Supplies$141.7M—
(Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, net-$19.4M—

FAQ

When did Regeneron Pharmaceuticals report Q2 2026 earnings?
Regeneron Pharmaceuticals (REGN) reported Q2 2026 earnings on July 30, 2026 before market open.
What were Regeneron Pharmaceuticals's Q2 2026 revenue and EPS?
Regeneron Pharmaceuticals reported revenue of $4.3B and adjusted eps of $14.29 for Q2 2026.
Did Regeneron Pharmaceuticals beat estimates in Q2 2026?
Revenue beat the consensus estimate of $3.8B by $473.4M. EPS beat the consensus estimate of $10.16 by $4.13.
How did Regeneron Pharmaceuticals's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 16.7% from $3.7B a year earlier.
Where can I find Regeneron Pharmaceuticals's Q2 2026 SEC filings?
You can read the 8-K earnings release (0000872589-26-000023) and the 10-Q periodic report (0000872589-26-000025) directly on SEC EDGAR. The filing index links above go to sec.gov.